USPTO serial 79433893
DEZAWA GOLDEN BAG
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- GARCIA, CLAUDIA
- Law office
- TMO LAW OFFICE 111
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with DEZAWA GOLDEN BAG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Anti-aging cosmetic preparations; anti-aging cream; anti-aging creams; anti-aging creams for cosmetic purposes; anti-aging creams for sun protection for the face and body; anti-aging masks for cosmetic purposes; anti-aging moisturisers; anti-aging moisturizers; anti-aging serums for cosmetic purposes; anti-aging serums for cosmetic use; anti-aging serums for sensitive skin; anti-aging skincare preparations; anti-aging sun protection creams for the face and body. | ACTIVE | — |
| 005 | Cells for medical purposes; cells for medical use; cellular function activating agents for medical purposes; cellulose esters for pharmaceutical purposes; cellulose ethers for pharmaceutical purposes; cellulose for pharmaceutical purposes; chemicals for cell separation and cultivation for medical or veterinary purposes; chemicals for separating and cultivating cells for medical or veterinary purposes; living cells for medical purposes; living cells for medical use; pharmaceutical compositions containing stem cells for the treatment of diseases; pharmaceutical preparations containing stem cells; pharmaceutical preparations for activating cellular function; stem cells for medical purposes; autoinjectors prefilled with pharmaceutical preparations; immunological products for intravenous injections; injectable medicinal solutions; injectable solutions for medical purposes; injectable solutions for use in inhibiting peristalsis for medical purposes; pharmaceutical preparations sold in pre-filled injectors; intravenous fluids used for the delivery of pharmaceutical preparations; intravenous solutions for medical purposes; immunosuppressive pharmaceutical preparations; pharmaceutical preparations for the treatment of cystic fibrosis; glycerophosphates; phosphates for pharmaceutical purposes; cardiovascular agents for medical purposes; cardiovascular pharmaceutical preparations; cardiovascular pharmaceuticals; cardiovascular preparations; cardiovascular treatment preparations; drugs for the treatment of cardiovascular diseases; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations and substances for the prevention of cardiovascular diseases and disorders; pharmaceutical preparations and substances for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the prevention of cardiovascular disorders; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations for treating cardiovascular diseases; pharmaceutical preparations for the prevention and treatment of kidney diseases; anti-ulcer agents; pharmaceutical preparations being antiulceratives; pharmaceutical preparations for the treatment of chronic liver diseases. | ACTIVE | — |
| 042 | Analysis of stem cells for medical research; cell culture services for scientific and research purposes, for others; culturing of cells for scientific research purposes; research and development in the field of microorganisms and cells; research and development services in the field of microorganisms and cells; research in the field of cell engineering technology; research of induced pluripotent stem cells; scientific services relating to the isolation and cultivation of human tissues and cells; stem cell research; stem cell research services. | ACTIVE | — |
| 044 | Human cell bank services; medical services relating to the removal, treatment and processing of stem cells; stem cell bank services; stem cell therapy services; medical services relating to the removal, treatment and processing of human cells; storage of human cells; storage of stem cells [stem cell bank services]; providing on-line information relating to the prevention of cardiovascular disease and strokes; medical services relating to the removal, treatment and processing of bone marrow; medical services relating to the removal, treatment and processing of umbilical cord blood; providing information relating to the treatment of cardiovascular and cerebrovascular diseases via the internet; health care services for treating Alzheimer's disease. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MUSECELL INNOVATIONS PTE. LTD.
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named DEZAWA GOLDEN BAG
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 13, 2026 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 13, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 5, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 5, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 21, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 21, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 18, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 17, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 11, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 3, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 2, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |